M&A news: EMC +5.2% (EMC confirms it will to be acquired by Dell for $67 billion in cash and stock deal; valued at $33.15 per share).
Select metals/mining stocks trading higher: HMY 6.3%, AU +6.1%, AUY +5.2%, HL +3.2%, GDX +2.7%, ABX +2.5%, GG +2.5%, NEM +2.5%, GOLD +1.8%, BBL +1.3%.
Other news: CANF +16.7% (granted Orphan Drug Designation by the EMA for CF102, for the indication of hepatocellular carcinoma), OREX +10.7% (Baupost Group discloses 17.17% passive stake in 13G filing), ESPR+10.6% (on LLY news), CLSN +8.7% (Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil), CETC +8.2% (continued strength), PSTG +6% (favorable commentary on Friday's Mad Money), RDUS +4.3% (announces positive top-line data from the Phase 3 ACTIVE trial), FRO +4.1% (still checking), LL +3.8% (continued strength), ONCE +3.4% (presents additional data from the Phase 3 pivotal trial as well as continued durability data from an earlier Phase 1 study of SPK-RPE65), INOV +2.8% (PMorgan Chase discloses 11% passive stake in 13G filing), SDRL +2.3% (still checking), FCAU +2.1% (Ferrari details plans for pending IPO, has applied to list on the NYSE under the symbol RACE; IPO to consist of 17,175,000 shares, expected price between $48.00-$52.00), PMTS +1.9% (IPO from Friday), TSLA +1% (to release software with autopilot this week), CS +0.9% (reports out that plans to lower costs by 7-10%), PSX +0.9% (announces 2016 capital budget of $3.6 bln, approves $2 bln increase to its share repurchase program), MON +0.3% (enters into a $3 bln accelerated share repurchase program).
Select metals/mining stocks trading higher: HMY 6.3%, AU +6.1%, AUY +5.2%, HL +3.2%, GDX +2.7%, ABX +2.5%, GG +2.5%, NEM +2.5%, GOLD +1.8%, BBL +1.3%.
Other news: CANF +16.7% (granted Orphan Drug Designation by the EMA for CF102, for the indication of hepatocellular carcinoma), OREX +10.7% (Baupost Group discloses 17.17% passive stake in 13G filing), ESPR+10.6% (on LLY news), CLSN +8.7% (Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil), CETC +8.2% (continued strength), PSTG +6% (favorable commentary on Friday's Mad Money), RDUS +4.3% (announces positive top-line data from the Phase 3 ACTIVE trial), FRO +4.1% (still checking), LL +3.8% (continued strength), ONCE +3.4% (presents additional data from the Phase 3 pivotal trial as well as continued durability data from an earlier Phase 1 study of SPK-RPE65), INOV +2.8% (PMorgan Chase discloses 11% passive stake in 13G filing), SDRL +2.3% (still checking), FCAU +2.1% (Ferrari details plans for pending IPO, has applied to list on the NYSE under the symbol RACE; IPO to consist of 17,175,000 shares, expected price between $48.00-$52.00), PMTS +1.9% (IPO from Friday), TSLA +1% (to release software with autopilot this week), CS +0.9% (reports out that plans to lower costs by 7-10%), PSX +0.9% (announces 2016 capital budget of $3.6 bln, approves $2 bln increase to its share repurchase program), MON +0.3% (enters into a $3 bln accelerated share repurchase program).
Analyst comments: NXPI +1.6% (light volume; resumed with a Overweight at Morgan Stanley; tgt $115), XOM +1.3% (upgraded to Equal Weight from Underweight at Barclays), NTAP +1.2% (upgraded to Outperform at Robert W. Baird; tgt raised to $40), GS +1.1% (upgraded to Buy from Neutral at Citigroup), AAPL +0.8% (target raised to $162 from $155 at Morgan Stanley)